The Texas Heart Institute
P

Takotsubo Cardiomyopathy: Can We Finally Clarify Its Cause and Pathophysiology?

By The Texas Heart Institute FEATURING Paolo Angelini
By The Texas Heart Institute FEATURING Paolo Angelini
108 views
January 5, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
Medical College of Georgia - Augusta University

Cardiovascular Summit at Kiawah Island Resort, SC 2024

Thu, Jul 18, 2024
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
17:22
Samuel Sherratt

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Has High Membrane Affi…

13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
17:29
UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
23:37
ACC 2024 Insights

ACC 2024 Insights: HFpEF Diagnosis - Key Factors to Consider

Feat. A. Misra
34:18
Scripps Health

Cancer Survivorship: How To Monitor for Cardiac Disease Following Tr…

Feat. A. Kuo
84:17
Jefferson Health

2022 Heart Failure Guidelines Review

Feat. D. Haas
20:59
Mary E. Money

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

13:53
American Heart & Vascular Institute

Cardiogenic Shock: Should IABP or PVADs Be Used in Cardiogenic Shock?

Feat. M. Ansari
28:48
MUSC Cardiology

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

Feat. S. Litwin
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava
11:26
Houston Methodist DeBakey Heart and Vascular Center

Aspirin for the Primary Prevention of Cardiovascular Disease: What C…

Feat. M. Miedema
27:52
Top Ten Topics in Clinical Cardiology 2023

Medical Management of Diastolic Dysfunction: Does The Emperor Finall…

Feat. S. Pinney